The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. reduced its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 10,681 shares of the medical device company’s stock after selling 386 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Cooper Companies were worth $982,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in COO. Victory Capital Management Inc. grew its position in Cooper Companies by 23.0% during the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock worth $435,856,000 after purchasing an additional 737,726 shares during the period. Raymond James Financial Inc. acquired a new stake in Cooper Companies during the 4th quarter worth about $64,826,000. JPMorgan Chase & Co. grew its position in Cooper Companies by 13.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock worth $543,979,000 after purchasing an additional 573,908 shares during the period. Alecta Tjanstepension Omsesidigt acquired a new stake in Cooper Companies during the 4th quarter worth about $49,550,000. Finally, Swedbank AB grew its position in Cooper Companies by 14.0% during the 4th quarter. Swedbank AB now owns 1,629,602 shares of the medical device company’s stock worth $149,809,000 after purchasing an additional 200,000 shares during the period. 24.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on COO. Wells Fargo & Company increased their price target on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Friday. Citigroup lowered their target price on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Friday. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Morgan Stanley lowered their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $111.89.

Cooper Companies Trading Down 6.6 %

COO stock opened at $85.00 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a 12-month low of $82.61 and a 12-month high of $112.38. The stock has a market cap of $16.96 billion, a price-to-earnings ratio of 43.59, a PEG ratio of 2.25 and a beta of 1.02. The business’s 50-day moving average is $92.38 and its 200 day moving average is $99.40.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. On average, sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.